NR4A2 and cardiac hypertrophy: Interestingly, NR4A2 overexpression also potently inhibited expression of the cardiac hypertrophy marker B-type natriuretic peptide (BNP) in both vehicle- and isoproterenol-treated ARVMs (Fig. 3C).